Literature DB >> 15922146

Neuropsychiatric lupus.

John G Hanly1.   

Abstract

Nervous system disease in patients who have systemic lupus erythematosus (SLE) spans a wide spectrum of neurologic (N) and psychiatric (P) features that may be attributed to a primary manifestation of SLE, complications of the disease or its therapy, or a coincidental disease process. The etiology of primary NP disease is multifactorial and includes vascular injury of intracranial vessels, autoantibodies to neuronal antigens, ribosomes and phospholipid-associated proteins, and the intracranial generation of cytokines. In the absence of a diagnostic gold standard for most of the NP-SLE syndromes, a range of investigations are employed to support the clinical diagnosis and determine the severity of NP disease. Treatment remains largely empiric in the absence of controlled studies, and current strategies include the use of immunosuppressive therapies, appropriate symptomatic interventions, and the treatment of non-SLE factors.

Entities:  

Mesh:

Year:  2005        PMID: 15922146     DOI: 10.1016/j.rdc.2005.01.007

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  24 in total

1.  Neurotoxic lupus autoantibodies alter brain function through two distinct mechanisms.

Authors:  Thomas W Faust; Eric H Chang; Czeslawa Kowal; RoseAnn Berlin; Irina G Gazaryan; Eva Bertini; Jie Zhang; Jorge Sanchez-Guerrero; Hilda E Fragoso-Loyo; Bruce T Volpe; Betty Diamond; Patricio T Huerta
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

Review 2.  SLE: translating lessons from model systems to human disease.

Authors:  Ram Raj Singh
Journal:  Trends Immunol       Date:  2005-09-09       Impact factor: 16.687

Review 3.  Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.

Authors:  Deana Lazaro
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

4.  Human lupus autoantibodies against NMDA receptors mediate cognitive impairment.

Authors:  Czeslawa Kowal; Lorraine A Degiorgio; Ji Y Lee; Mark A Edgar; Patricio T Huerta; Bruce T Volpe; Betty Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-14       Impact factor: 11.205

5.  Attribution in the assessment of nervous system disease in SLE.

Authors:  John G Hanly
Journal:  Rheumatology (Oxford)       Date:  2014-12-05       Impact factor: 7.580

6.  Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions.

Authors:  Hae Woong Jeong; Minyoung Her; Jong Seok Bae; Seong-Kyu Kim; Sung Won Lee; Ho Kyun Kim; Dongyook Kim; Nayoung Park; Won Tae Chung; Sang Yeob Lee; Jung-Yoon Choe; In Joo Kim
Journal:  Rheumatol Int       Date:  2014-10-15       Impact factor: 2.631

Review 7.  Integrative neuroscience approach to neuropsychiatric lupus.

Authors:  Patricio T Huerta; Elizabeth L Gibson; Carson Rey; Tomás S Huerta
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

8.  Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India.

Authors:  Nikhil Gupta; Arvind Ganpati; Santosh Mandal; John Mathew; Ruchika Goel; Ashish Jacob Mathew; Aswin Nair; Prakash Ramasamy; Debashish Danda
Journal:  Clin Rheumatol       Date:  2017-08-07       Impact factor: 2.980

Review 9.  Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.

Authors:  Mariana Postal; Lilian T L Costallat; Simone Appenzeller
Journal:  CNS Drugs       Date:  2011-09-01       Impact factor: 5.749

10.  Functional outcome after stroke in patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Tracy U Nguyen-Oghalai; Helen Wu; Terry A McNearney; Carl V Granger; Kenneth J Ottenbacher
Journal:  Arthritis Rheum       Date:  2008-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.